In Silico Estimation of DMSO Solubility of Organic Compounds for Bioscreening

Abstract

Solubility of organic compounds in DMSO is an important issue for commercial and academic organizations handling large compound collections or performing biological screening. In particular, solubility data are critical for the optimization of storage conditions and for the selection of compounds for bioscreening compatible with the assay protocol. Solubility is largely determined by the solvation energy and the crystal disruption energy, and these molecular phenomena should be assessed in structure-solubility correlation studies. The authors summarize our long-term experimental observations and theoretical studies of physicochemical determinants of DMSO solubility of organic substances. They compiled a comprehensive reference database of proprietary data on compound solubility (55,277 compounds with good DMSO solubility and 10,223 compounds with poor DMSO solubility), calculated specific molecular descriptors (topological, electromagnetic, charge, and lipophilicity parameters), and applied an advanced machine-learning approach for training neural networks to address the solubility. Both supervised (feed-forward, back-propagated neural networks) and unsupervised (Kohonen neural networks) learning methods were used. The resulting neural network models were validated by successfully predicting DMSO solubility of compounds in independent test selections. (Journal of Biomolecular Screening 2004:22-31)

References

1. Budavari S: The Merck Index: Encyclopedia of Chemicals, Drugs and Biologicals. Rahway, NJ: Merck and Co. , 1989.

2. Brown JH: Double-blind clinical study: DMSO for acute injuries and inflammations compared to accepted standard therapy . Curr Ther Res 1971;13: 536-540 .

3. Small A, Ide RS: Failure to detect nephrotoxicity of chronically administered dimethyl sulfoxide (DMSO) in rats . Cryobiology 1976;13: 328-333 .

4. Raegnier JF, Richard J: Lack of developmental toxicity in rats treated with dimethyl sulfoxide (DMSO) . Toxicologist 1998;42: 256-257 .

5. Murdoch LA: Dimethyl sulfoxide (DMSO): overview . Can J Hosp Pharm 1982;35: 79-85 .

6. Hagelman RF, Evans TC, Riley EF: Modification of radiation effect on eye by topical application of dimethyl sulfoxide . Radiat Res 1970;44: 368-342 .

7. Wood DC, Wood J: Pharmacologic and biochemical considerations of dimethyl sulfoxide . Ann NY Acad Sci 1975;243: 7-19 .

8. Lowelock JE, Bishop MWH: Prevention of freezing damage to living cells by dimethyl sulphoxide . Nature 1979;183: 1394-1395 .

9. Hochlowski J, Cheng X, Sauer D, Djuric S: Studies of the relative stability of TFA adducts vs non-TFA analogues for combinatorial chemistry library members in DMSO in a repository compound collection . J Comb Chem 2003;5: 345-350 .

10.

10. Kozikowski BA: The effect of freeze/thaw cycles on the stability of compounds in DMSO . Paper presented at the 7th Annual SBS Conference and Exhibition, Baltimore, September 2001.

11.

11. Turmel M, Spreen R, Nie D: Preliminary investigation of compound stability under various storage conditions . Paper presented at the Drug Discovery Congress, Boston, August 2002.

12.

12. Beckner C, Cheng X, Hepp D: Studies on compound stability in DMSO under different conditions . Paper presented at the Drug Discovery Congress, Boston, August 2002.

13.

13. Yaskanin D: Quality perspectives for compound storage . Paper presented at the Automated Compound Storage & Retrieval Meeting, Somerset, UK, January 2003.

14.

14. Fillers WS: Key factors affecting compound integrity . Paper presented at the Lab Automation Meeting, Palm Springs, CA, February 2003.

15.

15. Lipinski CA: Storage of samples in DMSO: issues and potential solutions . Paper presented at the SBS 8th Annual Conference and Exhibition, Hague, The Netherlands, September 2002.

16.

16. Gaylord Chemical Corp.: Solubility of active pharmaceutical compounds (APCs) in USP grade dimethyl sulphoxide (DMSO) [Online]. Retrieved from http://www.gaylordchemical.com/bulletins/PharmaSolubilities%20booklet%20bulletin.pdf

17.

17. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings . Adv Drug Delivery Rev 1997;23: 3-25 .

18.

18. Raevsky OA, Trepalin SV, Trepalina HP, Gerasimenko VA, Raevskaya OE: SLIPPER-2001: software for predicting molecular properties on the basis of physicochemical descriptors and structural similarity . J Chem Inf Comput Sci 2002;42: 540-549 .

19.

19. Scarsi M, Apostolakis J, Caflisch A: Comparison of a GB solvation model with explicit solvent simulations: potentials of mean force and conformational preferences of alanine dipeptide and 1,2-dichloroethane . J Phys Chem B 1998;102: 3637-3641 .

20.

20. Song X, Chandler D: Dielectric solvation dynamics of molecules of arbitrary shape and charge distribution . J Chem Phys 1998;108: 2594-2600 .

21.

21. Cui Q: Combining implicit solvation models with hybrid quantum mechanical molecular mechanical methods: a critical test with glycine . J Chem Phys 2002;117: 4720-4728 .

22.

22. Jensen L, van Duijnen PT, Snijders JG: Adiscrete solvent reaction field model within density functional theory . J Chem Phys 2003;118: 514-521 .

23.

23. Pierotti RA: A scaled particle theory of aqueous and nonaqueous solutions . Chem Rev 1976;76: 717-726 .

24.

24. Mezei M, Beveridge DL: Free energy simulations . Ann Acad Sci NY 1986;482: 1-23 .

25.

25. Straatsma TP, McCammon JA: Computational alchemy . Annu Rev Phys Chem 1992;43: 407-435 .

26.

26. Sadowski J, Kubinyi H: A scoring scheme for discriminating between drugs and nondrugs . J Med Chem 1998;41: 3325-3329 .

27.

27. Ajay A, Walters WP, Murcko MA: Can we learn to distinguish between drug-like and nondrug-like molecules? J Med Chem 1998;41: 3314-3324 .

28.

28. Balakin KV, Tkachenko SE, Lang SA, Okun I, Ivashchenko AI, Savchuk NP: Property-based design of GPCR-targeted library . J Chem Inf Comput Sci 2002;42: 1332-1342 .

29.

29. Lang SA, Kozyukov AV, Balakin KV, Skorenko AV, Ivashchenko AA, Savchuk NP: Classification scheme for the design of serine protease targeted compound libraries . J Comp-Aid Mol Des 2002;16: 803-807 .

30.

30. Anzali S, Gasteiger J, Holzgrabe U, et al: The use of self-organizing neural networks in drug design. In Kubinyi H, Folkers G, Martin YC (eds): 3D QSAR in Drug Design: Volume 2. Dordrecht, The Netherlands: Kluwer/ESCOM , 1998:273-299.

31.

31. Brüstle M, Beck B, Schindler T, King W, Mitchell T, Clark T: Descriptors, physical properties, and drug-likeness . J Med Chem 2002;45: 3345-3355 .

32.

32. Nikolsky Y, Balakin KV, Ivanenkov YA, Ivashchenko AA, Savchuk NP: Intelligent machine learning technologies in pre-synthetic combinatorial design . Pharma Chem 2003;4: 68-72 .